Sunflower Pharmaceutical strengthens investment oversight, revises governance documents

Sunflower Pharmaceutical Group has implemented new "Measures for the Administration of Outbound Investments," effective October 10, 2025. These measures centralize investment activities, define decision-making authority for the board, shareholders, and management, and outline roles for various departments in project assessment, execution, and oversight. The policy also details procedures for asset disposal and ongoing project monitoring to mitigate risks and enhance financial returns.

In a related development, the company's board of directors, during its eleventh meeting on October 10, 2025, approved a comprehensive set of revised management policies, including the "Outbound Investment Management Measures." This approval underscores the company's commitment to robust internal controls and regulatory compliance.

During the same meeting, the board also authorized a three-year trademark licensing agreement, allowing its controlling shareholder and subsidiaries to use specific "Sunflower" trademarks for a total fee of 150,000 yuan per year, starting January 1, 2026. The board further approved amendments to the company's articles of association and other governance documents.